Gathering the record
Relay is organizing the evidence and source boundaries.
Mitochondrial-derived peptide
Humanin is a mitochondrial-derived peptide studied as a cellular stress and survival signal.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Humanin is a small peptide encoded within mitochondrial genetic material. It acts as a cellular stress signal in laboratory systems and is measured naturally in human blood.
Cell and animal studies suggest links to survival, metabolism, aging, and neurodegeneration. Researchers want to know whether a defined Humanin-like product could reach relevant tissues without disrupting normal cell-death or growth control.
Human studies located by Relay measured naturally circulating Humanin and reported associations with age-related traits. Laboratory experiments mapped protective signaling, and a Humanin analog changed metabolic outcomes in mice. No administered-human efficacy study was located.
Human pharmacokinetics, target exposure, clinical benefit, route-specific safety, immune effects, growth and cancer implications, and long-term outcomes remain unknown. Observational biomarker associations do not show that adding Humanin causes benefit.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Published human research measured naturally circulating Humanin rather than administering a standardized Humanin product to test a clinical outcome.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Mechanistic, animal, and observational human biomarker evidence; no administered-human efficacy trial located.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Whether a defined Humanin analog can reach relevant tissues and improve clinical outcomes without disrupting normal cell-death or growth regulation.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Association between a natural biomarker and age-related traits does not establish causation or treatment benefit. The section remains incomplete because administered-human exposure, pharmacokinetic, efficacy, and safety evidence are absent. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Human evidence located by Relay is observational or biomarker-based rather than a trial of administered Humanin.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether a defined Humanin analog can reach relevant tissues and improve clinical outcomes without disrupting normal cell-death or growth regulation.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Mechanisms
Humanin and analogs influence apoptosis, metabolism, and stress-response pathways in laboratory and animal models. Human circulating-level associations do not prove that administration improves outcomes.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Observational biomarker study
Human cohorts
Endpoints were not fully described in the current record.
Circulating Humanin was measured in human cohorts and associated with age-related phenotypes.
Study administration: Not stated in the current record.
Limitations: Association does not establish causation or administered-peptide benefit.
Cell and molecular study
Population not stated.
Endpoints were not fully described in the current record.
Cell studies mapped protective signaling and receptor interactions.
Study administration: Not stated in the current record.
Limitations: Laboratory protection does not establish human efficacy or long-term safety.
Controlled animal study
Mice
Endpoints were not fully described in the current record.
A Humanin analog affected metabolic outcomes in mice.
Study administration: Not stated in the current record.
Limitations: Analog, exposure, and species differences limit translation.
Safety snapshot
No administered-human dose-ranging or longer-term safety record was located; growth and apoptosis pathways make broad safety assumptions inappropriate.
Other human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryPreclinical; no FDA-approved Humanin product. Whether a defined Humanin analog can reach relevant tissues and improve clinical outcomes without disrupting normal cell-death or growth regulation.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 32575074
PMID 15153530
PMID 30004252
No direct primary administration source was verified for this exact identity. The limitation is the finding.